NephroDI is a pre-clinical stage company developing an oral small molecule drug for genetic (X-Linked) and drug induced (Tolvaptan and Lithium induced) Nephrogenic Diabetes Insipidus (NDI). The compound activates AMPK to increase function of aquaporin-2 channels into the collecting duct cells of the kidney, thereby restoring the ability to concentrate urine.
Sound Contact: Johan Kördel (Board Director)
Read an interview with CEO, Rachael Hagan: Navigating the journey of orphan drug development
